About the Company
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development.
T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.
Scientist – Pipeline – Protein Engineering
About the Opportunity
We are seeking a Protein engineering scientist to join our Pipeline team. The team is developing an in-vitro yeast-based selection platform to generate high quality molecules for TCR-based therapies. The role is primarily lab-based, and includes both verbal and written communication, along with the requirement for good organisation and a broad scientific knowledge. This an excellent opportunity to contribute to the development of advanced medicines that can impact the lives of patients around the world.
In this role you will be responsible for:
- Molecular biology and protein engineering of TCRs
- Generation of yeast display libraries for TCRs
- Performing of yeast display and flow-based selection techniques to select for improved TCR affinities
- Development and application of latest single cell sequencing technology for TCR discovery
- Development and application of novel approaches for TCR discovery
- Work with bioinformaticians to shortlist TCR candidate sequences
- Work with project teams to shortlist candidate TCRs
- Trouble shooting and technology development
- Establishment, review, and updates of SOPs
- Precise recording of daily laboratory work
- Verbal and written communication to colleagues
- This role will also likely include management responsibilities as the company grows
- PhD or equivalent practical work experience in a relevant field of molecular biology or biotechnology, with a track record of impactful work.
- Extensive experience of antibody or TCR selections and affinity optimisation techniques, such as yeast display, and library selection/screening-based protein engineering techniques.
- Demonstrated experience with cytometry techniques such as Flow/FACS.
- Ability to perform a wide range of molecular biology techniques such as PCR, sequence analysis, various cloning techniques.
- Track record of contributing to new research directions and/or novel scientific strategies.
- Ability to perform complex data interpretation to design next logical experiment.
- Excellent communication skills for reporting (written & presentation) and experimental lab book write-ups.
- Quick to learn the use of lab instrumentation and new experimental techniques.
- Experience of effective team and matrix working in a dynamic environment.
- Analytical techniques to profile a large panel of biopharmaceuticals (based on their biophysical and chemical stability properties).
- Ability to multi-task and work across multiple projects simultaneously.
Experience in some of the areas listed below would be advantageous:
- Methods to measure binding affinities such as Biacore and other SPR techniques for characterization of TCRs.
- Analytical techniques to profile panels of biopharmaceuticals (based on their biophysical and chemical stability properties).
T-Therapeutics offers employees a wide range of benefits. These include a generous pension contribution, life insurance, health insurance and a health cash plan. Employees will be offered share options in the company, as well as 28 days’ holiday each year (not including standard bank holidays).
You will have the opportunity to contribute to innovative drug development, in an open environment, able to learn all aspects of drug development. T-Therapeutics is also committed to enabling staff to grow professionally in a variety of ways as well as providing the chance to develop cutting-edge technologies.